Fig. 3: In vitro combination of BI 894999: proliferation and pathway modulation.
From: Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic
a BI 894999 combined with various partners (HDACi Panobinostat and romidepsin, p300/CBPi CCS1477, GNE-781 and A485) in NC cell line Ty-82 and analysed for Bliss synergy. Combination platemap in a 6 × 6 matrix (duplicates for each setting) at the indicated concentrations. CGI (cell growth inhibition) Values <100%: tumour cell growth, CGI 100%: tumour cell stasis and GCI > 100%: tumour cell killing. b Incucyte life cell imaging analysis: BI 894999 combined with CCS1477 in four NC cell lines. Graphs are shown for 1 nM BI 894999 and 12 nM CCS1477 over 7 days of continuous treatment. c HEXIM1 expression analysis by RNA-seq in 4 NC cell lines. Cells were treated for 4 h with DMSO control, 10 nM BI 894999, 300 nM CCS1477 or a combination of both. Expression values in CPM (counts per million). Increased induction of HEXIM1 upon combination.
